BioMarin's VOXZOGO Shows Sustained Growth Benefits in Hypochondroplasia, BMN 333 Advances Toward Late-Stage Trials
Event summary
- BioMarin presented three-year data from a Phase 2 extension study of VOXZOGO in hypochondroplasia, showing sustained improvements in growth metrics and a favorable safety profile.
- BMN 333, a long-acting C-type natriuretic peptide, demonstrated sustained systemic exposure and potential for weekly dosing in a Phase 1 study.
- BioMarin plans to submit a supplemental New Drug Application for VOXZOGO in hypochondroplasia in Q3 2026.
- Enrollment has begun for a Phase 2/3 study of BMN 333, with a data update expected in 2027.
The big picture
BioMarin's data reinforces its leadership in treating skeletal dysplasias, with VOXZOGO potentially expanding into hypochondroplasia and BMN 333 offering a next-generation treatment option. The company's strategic focus on rare diseases positions it to capture significant market share in an underserved therapeutic area. The success of these programs could drive long-term revenue growth and solidify BioMarin's position as a key player in the biotechnology sector.
What we're watching
- Regulatory Pathway
- Whether the FDA will approve VOXZOGO for hypochondroplasia based on the Phase 3 and extension study data.
- Clinical Development
- The pace at which BMN 333 advances through late-stage trials and its potential to become a standard of care for achondroplasia.
- Market Opportunity
- How BioMarin will position VOXZOGO and BMN 333 in the growing rare disease treatment market.
Related topics